MediWound Ltd. (MDWD) stock
Close on Nov 12, 2026Market cap $166.47MP/E –Yield –
MediWound Ltd. saw revenue fall 16.1% to $16.96M over fiscal 2025. Free cash flow was -$21.63M. At the latest close the market valued the company at $166.47M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $166.47M
- P/E ratio
- –
- Price to sales
- 9.82
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -12.99%
Fundamentals
- Revenue
- $16.96M
- EPS, diluted
- -$2.10
- Free cash flow
- -$21.63M
- Diluted shares
- 13M
Trading
- Previous close
- $13.82
- Open
- $12.60
- Day's range
- $12.46 – $13.53
- Volume
- 354,543
- Average volume (20 days)
- 161,419
- Beta (5 years)
- 0.90
- 52-week range
- $11.80 – $19.70
- RSI (14 days)
- 47.0
- Volatility (1 year)
- 42.5%
- Relative volume
- 3.60×
- WACC
- 9.4%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MDWD | S&P 500 | Difference | MDWD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.3% | -2.7% | +6.0 pts | ||
| 3 months | -6.8% | -1.7% | −5.0 pts | ||
| Year to date | -29.7% | +11.9% | −41.6 pts | ||
| 1 year | -28.8% | +12.0% | −40.8 pts | ||
| 3 years | +68.4% | +78.2% | −9.7 pts | +19.0% | +21.2% |
| 5 years | -44.4% | +73.2% | −117.6 pts | -11.1% | +11.6% |
| 10 years | -68.1% | +309.6% | −377.7 pts | -10.8% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases MediWound filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About MediWound
Medicinal Chemicals & Botanical Products
MediWound Ltd. is a biopharmaceutical company that develops and commercializes therapeutics for burn care and wound management. Its primary products and pipeline product candidates include NexoBrid and EscharEx. The company serves healthcare providers and institutional partners, collaborating with government organizations such as the United States Biomedical Advanced Research and Development Authority, commercial pharmaceutical partners including Vericel and Teva, and regional burn centers and medical units.
Company profile, executives and historyMediWound stock: common questions
What is MediWound's stock price?
MDWD closed at $12.97 on Nov 12, 2026, down 6.15% on the day. Over the past 52 weeks it traded between $11.80 and $19.70.
What is MediWound's market cap?
MediWound was worth $166.47M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MDWD's P/E ratio?
MediWound lost money over fiscal 2025 (diluted EPS -$2.10), so it has no meaningful P/E ratio.
How much revenue does MediWound make?
MediWound reported revenue of $16.96M for fiscal 2025, down 16.1% from a year earlier.
Does MediWound pay a dividend?
No. MediWound has not paid a cash dividend over the last twelve months.
How has MDWD stock performed over the past year?
Including dividends, MDWD returned -28.8% over the past year, against +12.0% for the S&P 500.
How many MDWD shares are sold short?
2M shares were sold short at the latest FINRA report, 18.07% of the float, or 14.7 days of average trading volume.
Who are MediWound's competitors?
Companies most similar to MediWound by business, industry and size include BON, PRQR, SLGL, EMMA, IMCC.
See a number that looks wrong?